Hidden amyloid in heart valves: a new clue in aortic stenosis?
NCT ID NCT04636684
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is examining heart valve tissue from 100 people undergoing surgery for aortic stenosis to see how often ATTR amyloid deposits are present. Researchers will use mass spectrometry to identify the type of amyloid. The goal is to better understand the link between amyloidosis and aortic valve disease.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could clarify how often ATTR amyloidosis affects heart valves, potentially guiding future diagnosis or treatment approaches.
- What could go wrong
- This is an observational study with no treatment being tested. It only looks at tissue samples and does not directly improve patient outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2020
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 99 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient over 18 years old * Degenerative aortic stenosis * Aortic valve replacement surgery * Signature of the informed consent form Exclusion Criteria: * Non-degenerative aortic stenosis: bicuspid, rheumatic disease, aortic regurgitation * Persons under a system of legal protection for adults (guardianship, curatorship, etc.) * Pregnant women
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Amyloidosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
university hospital center Toulouse
RECRUITINGToulouse, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Banking blood and bone marrow to decode plasma cell disorders
- Can a single scan reveal hidden amyloid deposits across the body?
- A simple heart scan may unmask a hidden cause of heart failure
- A hidden warning in your wrist? surgery may reveal heart risk
- Can a daily pill keep a rare heart disease in check for the long haul?
- Heart drug acoramidis tested for Long-Term cardiac repair in rare amyloidosis